Pouletty attributes Abivax's success to its drug's mechanism, which boosts a natural microRNA to slow inflammation. He extends this into a broader principle for biotech and medtech: it's better to develop products that mimic or leverage the body's existing systems, honed by millions of years of evolution, rather than trying to impose entirely new ones.
Truffle Capital's strategy for Abivax was to merge three of its portfolio companies. This created critical mass, a multi-asset pipeline that could withstand the failure of its lead drug candidate, and a more attractive profile for attracting top-tier management and significant capital through a large IPO. This model is now being replicated with Carvolix.
Carvolix is strategically designing its robotic and AI platform to be compatible with heart valves from all major manufacturers like Edwards and Medtronic. This "agnostic" approach allows them to sell *to* the entire ecosystem rather than competing *within* it, positioning their technology as a universal upgrade that any hospital can adopt regardless of its preferred valve supplier.
Philippe Pouletty argues against the political celebration of creating numerous small startups. He contends that the true measure of success for a nation's innovation ecosystem, like in the US, is its ability to scale companies into independent, globally dominant leaders, rather than just generating a high volume of new ventures.
Philippe Pouletty compares his vision for Carvolix's AI-driven robotic surgery to modern aviation. Just as GPS and automation make flying safer and accessible to more pilots, Carvolix uses AI and robotics to simplify complex cardiac procedures, enabling less-experienced cardiologists to perform them safely and effectively, thus expanding patient access.
Pouletty warns that while a NASDAQ listing provides capital, it often leads to US investor pressure to replace European leadership with American executives. This shift in management can change the company's culture and center of gravity, ultimately making it an American company that is more easily acquired by US pharma giants.
Instead of just seeking venture funding, Philippe Pouletty started Truffle Capital to have the financial "firepower" to create and grow biotech companies on his own terms. This unique approach allowed him to make decisions decisively, like a doctor, and avoid the complications and compromises of involving too many co-investors in the early stages.